Hyperoside

Hyperoside is a flavonoid glycoside composed of quercetin linked to galactose, found naturally in plants such as St. John's Wort, hawthorn, and various Hypericum species. It exerts its primary effects through antioxidant activity, modulation of the PI3K/Akt signaling pathway, and regulation of apoptotic proteins including caspases and p53.

Origin & History

Hyperoside is a flavonoid glycoside, specifically quercetin 3-O-β-D-galactopyranoside, found naturally in plants like Camellia species. It is obtained through plant extraction or synthesized chemically using quercetin or rutin as starting materials via regioselective glycosylation.

Historical & Cultural Context

No historical or traditional medicinal uses for hyperoside are documented in the available research sources.

Health Benefits

• Anti-cancer effects in HeLa cells have been observed, involving upregulation of caspases and p53, and downregulation of Nampt and Sirt1 [Preclinical evidence]. • Shows potential neuroprotective actions via the PI3K/Akt pathway [Preclinical evidence]. • Exhibits antioxidant activity due to hydroxyl groups, which may help in reducing oxidative stress [Preclinical evidence]. • Potential renoprotective effects are suggested by its mechanism of action [Preclinical evidence]. • Binds to 3CL protease of HCoV-229E, indicating possible antiviral properties [Preclinical evidence].

How It Works

Hyperoside scavenges reactive oxygen species through its hydroxyl groups on the quercetin backbone, donating electrons to neutralize free radicals. In cancer cell models, it upregulates pro-apoptotic caspase-3 and caspase-9 and tumor suppressor p53 while downregulating the NAD-biosynthetic enzyme Nampt and the deacetylase Sirt1, shifting the cell toward programmed death. Neuroprotective effects are mediated through activation of the PI3K/Akt survival pathway, which suppresses pro-apoptotic signaling in neuronal cells under oxidative or ischemic stress.

Scientific Research

No human clinical trials, RCTs, or meta-analyses on hyperoside were identified in the available sources. Evidence is limited to preclinical in vitro studies such as those conducted on HeLa cells.

Clinical Summary

The current evidence base for hyperoside is derived almost entirely from in vitro cell studies and rodent models, with no completed large-scale human clinical trials specifically isolating hyperoside as an intervention. Anticancer activity has been demonstrated in HeLa cervical cancer cell lines, where hyperoside induced measurable increases in caspase activation and p53 expression. Neuroprotective effects have been observed in mouse models of cerebral ischemia, showing reduced infarct volume and improved behavioral outcomes, though effect sizes cannot yet be extrapolated to humans. Overall, the evidence is promising but classified as preclinical, and robust randomized controlled trials in humans are absent.

Nutritional Profile

Hyperoside (quercetin-3-O-β-D-galactoside; C21H20O12; MW 464.38 g/mol) is a flavonol glycoside, not a food or nutrient per se, and therefore does not possess a conventional macronutrient profile (no significant protein, fat, carbohydrate, or fiber contribution at pharmacologically relevant doses). Key characteristics: • Bioactive classification: Flavonoid glycoside (subclass: flavonol-O-glycoside), consisting of the aglycone quercetin linked via a β-glycosidic bond to D-galactose at the 3-position. • Natural occurrence and approximate concentrations: Found in Hypericum perforatum (St. John's Wort) leaves (~2–5 mg/g dry weight), Crataegus spp. (hawthorn) leaves and berries (~1–4 mg/g dry weight), Artemisia capillaris, Cuscuta chinensis seeds, and various Rhododendron species. Also present in lower amounts in apples, pears, and cranberries (<0.1–0.5 mg/g fresh weight). • Key functional groups: Five phenolic hydroxyl groups (positions 3', 4' on B-ring; 5, 7 on A-ring; and indirectly via the sugar moiety), which are primarily responsible for its radical-scavenging and metal-chelating antioxidant capacity. DPPH radical scavenging IC50 is approximately 5–15 µM depending on assay conditions. • Bioavailability notes: Oral bioavailability is relatively low (estimated <5% in rodent models) due to extensive first-pass metabolism. In the gut, hyperoside is hydrolyzed by intestinal β-galactosidase to release free quercetin and galactose; quercetin is then further conjugated (glucuronidation, sulfation, methylation) in enterocytes and hepatocytes. Primary circulating metabolites include quercetin-3'-O-glucuronide, isorhamnetin-3-O-glucuronide, and quercetin-3'-O-sulfate. Colonic microbiota can further degrade unabsorbed hyperoside into smaller phenolic acids (e.g., 3,4-dihydroxyphenylacetic acid, 3-hydroxyphenylacetic acid). Peak plasma concentrations of total quercetin metabolites following oral hyperoside dosing in rodents (~50–100 mg/kg) reach approximately 1–10 µM. Galactose conjugation at C-3 may confer slightly different intestinal absorption kinetics compared to quercetin-3-O-glucoside (isoquercitrin) due to substrate specificity of SGLT1 and lactase-phlorizin hydrolase. • Solubility: Moderately soluble in ethanol and methanol; poorly soluble in water (~0.6 mg/mL at 25 °C), which limits oral absorption of the intact glycoside. Solubility improves in slightly alkaline or DMSO-based formulations. • No vitamins or minerals are intrinsic to the compound itself; any associated micronutrient content would derive from the plant matrix in which hyperoside naturally occurs.

Preparation & Dosage

There are no clinically studied dosage ranges for hyperoside in humans. Preclinical in vitro studies used concentrations of 100 μmol/L or 400 μg/mL. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Rutin, Resveratrol, Curcumin, EGCG

Safety & Interactions

Hyperoside has not been evaluated for safety in rigorous human clinical trials, so a formal adverse effect profile has not been established. Because it is structurally derived from quercetin, potential interactions with cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9, are theoretically possible, which could affect metabolism of anticoagulants, statins, or immunosuppressants. Hyperoside is frequently consumed as part of St. John's Wort extracts, and any formulation containing St. John's Wort carries well-documented interactions with serotonergic drugs, oral contraceptives, and cyclosporine due to CYP and P-glycoprotein induction. Pregnant and breastfeeding individuals should avoid isolated hyperoside supplementation due to a complete lack of safety data in these populations.